CNBC·3 min read·medium
AstraZeneca and Bristol Myers Squibb mull $400 billion deal: Report
A
Annie Nova
✦AI Summary
AstraZeneca is reportedly in discussions to merge with Bristol Myers Squibb in a deal that could value the combined entity at approximately $400 billion. If completed, this would represent one of the largest pharmaceutical mergers in history.
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb , in a deal that would value the joint company at roughly $400 billion, the Financial Times reported on Sunday.
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in